TY - JOUR AU - N Arseni, AU - F Ahmed, AU - W Hiddemann, AU - C Buske, AU - M Feuring-Buske, PY - 2005/11/01 Y2 - 2024/03/29 TI - Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells JF - Haematologica JA - haematol VL - 90 IS - 11 SE - Comparative Studies DO - 10.3324/%x UR - https://haematologica.org/article/view/3723 SP - 1577-1578 AB - FLT3 activating mutations are the most frequent single genetic abnormality in patients with acute myeloid leukemia. Thus targeting the FLT3 activated kinase is a promising treatment approach. We wanted to test whether the protein tyrosine kinase inhibitor SU5614 selectively eliminates leukemic stem cells while sparing their normal counterparts. ER -